On August 5, CVS Health fell 9.74% in regular trading, trading at $94.74/share with turnover of $175 million, reversing earlier pre-market gains of over 5% following a strong Q2 earnings beat.

Despite reporting Q2 adjusted EPS of $2.58 versus the $1.85 consensus estimate — a 39.4% beat — and revenue of $106.1 billion versus the $100 billion estimate, the stock sharply reversed after a senior executive disclosed that market pressure from the 340B drug discount program is expected to persist into 2027, significantly weighing on the pharmacy services segment. The company also raised its full-year adjusted EPS guidance to $7.90-$8.10, up from $7.30-$7.50, well above the $7.45 analyst consensus.

However, management simultaneously reiterated a cautious stance for the remainder of the year, citing persistently elevated cost trends and potential macroeconomic headwinds that could suppress core business growth. Analysts noted that if inflation or labor market volatility intensifies, profitability could face further pressure, effectively offsetting the positive earnings surprise and triggering the intraday selloff.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)